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ABSTRACT 
A new, simple, novel, accurate, precise, reliable, rapid and linear reverse phase high-performance liquid chromatography (RP-HPLC) method 
was developed and fully validated for simultaneous qualitative and quantitative estimation of   Rosuvastatin (ROS), Clopidogr el (CLOP) and 
Aspirin (ASP) in bulk and pharmaceutical dosage form as per International Conference on Harmonization (ICH) guidelines. In the present work, 
good chromatographic separation was achieved by isocratic method using a Hypersil BDS C18 column (250 mm ×4.6, 5 μm) and a mobile phase 
consisting of KH2Po4 buffer pH-6.0: acetonitrile in the ratio 60:40, at a flow rate of 1 ml/min. The effluents obtained were monitored at 242nm 
with the UV-visible detector. The calibration curves obtained were linear (r2=0.999) over the concentration range of 7.5-22.5μg/ml and 1-
3μg/ml for CLOP, ASP and ROS respectively. A run time of 7.0 minutes for each sample made it possible to analyze more than 200 samples per 
day. The retention time of ASP, CLOP and ROS was found to be 3.103 min, 4,277 min and 5.707 min respectively. The high recovery values 
(99%-101%) indicate a satisfactory accuracy. The low percent relative standard deviation (% RSD) values in the precision study reveal that the 
method is precise  therefore the method can be used for routine monitoring of CLOP, ASP and ROS in industry in the assay of bulk drug and 
dosage form. 
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INTRODUCTION 
Platelet aggregation and thrombus formation play a critical 
role in the initiation and development of key complications 
of acute coronary syndromes (ACSs). HMG-CoA Reductase 
catalyzes the conversion of HMG-CoA to mevalonic acid, the 
rate-limiting step in cholesterol biosynthesis and it is used to 
reduce plasma cholesterol levels and prevent cardiovascular 
disease (CVD), antiplatelet therapy and antithrombotic 
therapy have been demonstrated to modify clinical outcome 
favorably, and recent trials of revascularization in ACSs have 
demonstrated a reduction in the frequency of major cardiac 
events1-3. Yet, all effective antithrombotic agents also 
increase the risk of bleeding. Especially bleeding that result 
from vascular accessories associated with surgery, including 
coronary artery bypass grafting (CABG)4-6.  Aspirin (ASP) 
(Fig.1A) is a well-known antithrombotic, antipyretic, 
analgesic agent. Chemically 2-(acetyloxy) benzoic acid, it is 
official in USP-NF7, BP8 and IP9. It is an antiplatelet agent 
approved by the Food and Drug Administration, USA, for use 
in secondary prevention of heart attacks and stroke10,11. 
Besides it is mainly used as an analgesic, antipyretic, anti-
inflammatory and antithrombotic agent. Clopidogrel (CLOP) 
(+)-(S)-methyl2- (2-chlorophenyl)-2-(6,7-dihydrothieno[3,2-
c] pyridin-5(4H)-yl) acetate (Fig.1B), is a new thienopyridine 
derivative. It is an antiplatelet agent, which selectively 
inhibits the binding of adenosine diphosphate (ADP) to its 
platelet receptor and blocks the subsequent ADP-mediated 
activation of the glycoprotein GPIIb/IIIa complex, thereby 
inhibiting platelet aggregation12. It is official in USP-NF13. It 
has been shown to prevent ischemic stroke, myocardial 
infarction and vascular disease and has demonstrated its 
clinical efficacy superior to that of aspirin. Thus, clopidogrel 
is indicated for the patients with atherosclerosis documented 
by recent stroke, recent myocardial infraction or 
cardiovascular disease14. Rosuvastatin (ROS) is the calcium 
salt of 7-[4-(4-fluorophenyl)-2-[methyl (methylsulfonyl) 
amino]-6-propan-2-ylpyrimidin-5-yl]-3, 5- dihydroxyhept-6-
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enoate (Fig.1C). ROS is a selective and competitive inhibitor 
of 3‐hydroxy‐3‐methylglutaryl‐coenzymeA (HMG‐CoA) 
reductase, the rate‐limiting enzyme that converts 
3‐hydroxy‐3‐methylglutaryl coenzyme A to mevalonate, a 
precursor of cholesterol. ROS is a member of the class of 
statins, used to treat hypercholesterolemia and related 
conditions and to prevent cardiovascular disease. It 
increases the number of hepatic LDL (Low Density 
Lipoprotein) receptors on the cell surface to enhance uptake 
and catabolism of LDL. Secondly, ROS inhibits hepatic 
synthesis of VLDL (Very Low Density Lipoprotein), which 
reduces the total number of VLDL and LDL particles15.The 
combination of aspirin, rosuvastatin and clopidogrel is 
available in the market as a capsule and tablet dosage form 
and is choice of drug for treatment of heart attack 
prevention. Rosumac gold manufactured by Macleod 
pharmaceuticals was used for RP-HPLC study. The strengths 
of the drug in the capsule chosen are aspirin 75 mg, 
rosuvastatin 10 mg and clopidogrel 75 mg.  Several analytical 
methods that have been reported for the estimation of ASP, 
CLOP and ROS in biological fluids and/or pharmaceutical 
formulations individually or combination with other drugs 
include UV, RP- HPLC and HPTLC16-23. Few methods were 
developed for estimation of these 3 dug in pharmaceutical 
dosage form by UV and HPLC. But reported method was time 
consuming, total RT was found to be 16 min24-26. Therefore, 
an attempt was made to develop a new, rapid and sensitive 
method for the simultaneous determination of ASP, CLOP 
and ROS with total run time 7.0 min. To access the 
reproducibility and wide applicability of the developed 
method, it was validated as per ICH norm, which is 
mandatory also27, 28. 
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Figure 1 Structure of (A) Aspirin (B) Clopidogrel (C) Rosuvastatin 
 
MATERIALS AND METHODS 
Instrument 
Liquid chromatographic system from Shimadzu (LC-20AT) 
comprising of manual injector, double reciprocating plunger 
pump LC-20ATVp for constant flow and constant pressure 
delivery and Photodiode array detector SPD-M20A 
connected to software LC solution for controlling the 
instrumentation as well as processing the data generated 
was used. 
Chemicals and reagents 
Analytically pure sample of ASP, CLOP and ROS was a 
generous gift from Yash Pharma Laboratories Pvt. Ltd. 
Mumbai, India. Potassium di hydrogen phosphates (AR 
grade), Disodium hydrogen phosphate (AR grade), glacial 
acetic acid and acetonitrile (HPLC Grade) was purchased 
from E. Merck Ltd. Worli, Mumbai, India. The 0.45μm nylon 
filters were purchased from Advanced Micro Devices Pvt. 
Ltd. Chandigarh, India. All excipients used were of 
pharmaceutical grade. Triple distilled water was generated 
in house. 
Diluents 
A mixture of acetonitrile: phosphate buffer pH- 6.0 (40:60 % 
v/v) was used in RP-HPLC as diluents. 
Selection of mobile phase 
Initially to estimate ASP, CLOP and ROS simultaneously, 
number of mobile phases in different ratios was tried. 
Taking into consideration the system suitability parameter 
like RT, tailing factor, number of theoretical plates and 
HETP, the mobile phase was found to be most suitable for 
analysis was acetonitrile: phosphate buffer pH-6.0 (40:60 % 
v/v), run as isocratic system. The mobile phase was filtered 
through 0.45 m filter paper and then degassed by Sonication. 
Flow rate employed for analysis was 1 ml/min. 
 
Chromatographic conditions 
The isocratic mobile phase consisted of acetonitrile: 
phosphate buffer pH-6.0 in the ratio of 40:60 (v/v), flowing 
through the column at a constant flow rate of 1.0 ml/min. A 
Hypersil BDS C18 column (5 μm, 150mm × 4.60mm) was 
used as the stationary phase. By considering the 
chromatographic parameter, sensitivity and selectivity of 
method for two drugs, 242nm was selected as the detection 
wavelength for UV-PDA detector. The HPLC system was 
operated at room temperature 25°C. 
Preparation of stock solution 
Accurately weighed 100 mg of ASP, CLOP and ROS were 
transferred into 100 ml volumetric flasks separately and 
dissolved in 50 ml of diluent, then volume was made up to 
100 ml with diluent to get a concentration of 1000μg/ml 
(Stock-A) for all three drugs. 
Preparation of sub stock solution 
5 ml of solution was taken from stock-A of ASP, CLOP and 
ROS and transferred into 50 ml volumetric flask separately 
and diluted up to 50 ml with diluent to give concentration of 
100μg/ml (Stock-B). From stock-B a series of dilution was 
made in the range of 7.5-22.5μg/ml for ASP, CLOP and 1-
3μg/ml for ROS respectively. 
System suitability parameters 
Separation variable was set and mobile phase was allowed 
to saturate the column at 1ml/min. After complete 
saturation of column, six replicates of reference standard, 
15μg/ml and 2μg/ml of ASP, CLOP and ROS respectively 
were injected separately. Peak report and column 
performance report were recorded at 242 nm for all 
chromatogram. 
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Preparation of calibration curve standards and quality 
control samples 
To establish the linearity of analytical method, a series of 
dilution ranging from 7.5-22.5μg/ml for ASP, CLOP and 1-
3μg/ml for ROS was prepared in the same manner as 
described above. All the solution were filtered through 0.2 
mm membrane filter and injected, chromatograms were 
recorded at 242 nm and it was repeated for five times. A 
calibration graph was plotted between the mean peak area 
and respective concentration and regression equation was 
derived.  
Stability study 
Samples prepared for repeatability study were preserved for 
24 h at room temperature and analyzed on the following day 
to test for short-term stability. 
Preparation for analysis of capsule formulation 
Twenty capsules were taken and their average weight was 
determined. They are crushed to fine powder; amount 
equivalent to 10 mg of ROS was taken in 100-ml volumetric 
flask. The ASP and CLOP present in this amount of tablet 
powder was 75 mg and the ratios of all three drugs were 10: 
75:75. This was than dissolve in 50 ml of diluent by 
sonication for about 10 minutes. The volume was made upto 
the mark by diluents and filtered by Whatmann filter paper 
(no. 41) and the filtrate was used to prepare samples of 
different concentration. Now all the tablet samples was 
scanned in multi photometric mode and the concentration of 
all three drugs were obtained from the equation. 
Validation of method 
As per ICH guideline the method was validated and following 
parameters were evaluated. 
Linearity 
Linearity of ASP, CLOP and ROS was established by response 
ratios of drug. The response ratios (response factor) were 
calculated by dividing the AUC with respective 
concentration. The curve was plotted between response 
ratios and concentration which shows the good linearity of 
drugs in the concentration ranging from 7.5-22.5μg/ml for 
ASP, CLOP and 1-3μg/ml for ROS respectively. 
Specificity 
Specificity of the method was carried out to assess 
unequivocally the analyte presence of the components that 
might be expected to be present, such as impurities, 
degradation products and matrix components. 
Precision 
Precision was determined by repeatability, Intermediate 
precision and reproducibility of all three drugs. 
Repeatability 
The repeatability was performed for five replicate at five 
concentrations in linearity range for ASP, CLOP and ROS that 
indicates the precision under the same operating condition 
over short interval time. 
Intermediate precision 
Day to day precision 
Intermediate precision was also performed within 
laboratory variation on different days for all three drugs 
simultaneously in five replicate at five concentrations. 
Analyst- to- analyst precision 
Analyst to analyst variation was performed by different 
analyst in five replicate at five concentrations. 
Reproducibility 
The reproducibility was performed by chemical to chemical 
(use of Rankem chemicals in place of Merck chemicals) 
variation in five replicate at five concentrations. 
Accuracy (% recovery) 
This study was carried out using pre analyzed tablet 
solution. A definite concentration of pure drug was added 
(80 %, 100 % and 120 % level) and then recovery was 
studied. A pre analyzed tablet solution containing 7.5μg/ml 
of ASP 1μg/ml of ROS and 7.5μg/ml of CLOP were taken in 
10 ml volumetric flasks and known concentrations of pure 
drug solution was added to them, which were prepared from 
standard stock solution of ASP, CLOP and ROS. It was 
repeated at 5 concentrations and 3 replicate levels. 
Calculation was done from the label claim and the average 
weight of the final product. 
Robustness 
As per ICH norms, small, but deliberate variations in flow 
rate, pH and concentration of the mobile phase were made to 
check the method’s capacity to remain unaffected.  
1. Flow rate of mobile phase was changed (± 0.2 ml/min) 0.8 
ml/min and 1.2 ml/min. 
2. pH of Mobile phase  was changed ( ± 0.2 )  6.2 and 5.8. 
3. Ratio of Mobile phase was changed (±2) Buffer: Acetonitrile 
(58:42) and Buffer: Acetonitrile (62:38) 
LOD and LOQ 
The LOD and LOQ of developed method were calculated 
based on the standard deviation of response and slope of the 
linearity curve. 
RESULTS AND DISCUSSION 
Method development 
The goal of this work was to develop and validate a simple, 
rapid and sensitive assay method for the quantitative 
determination of ASP, CLOP and ROS from capsule dosage 
form. Initially to estimate ASP, CLOP and ROS 
simultaneously number of mobile phases in different ratios 
was tried. Taking into consideration the system suitability 
parameter (Table 1) like RT, tailing factor, number of 
theoretical plates and HETP, the mobile phase was found to 
be most suitable for analysis was acetonitrile: KH2Po4 buffer 
pH-6.0 (40:60 % v/v), run as isocratic system. The mobile 
phase was filtered through 0.45 m filter paper and then 
degassed by sonication. Flow rate employed for analysis was 
1.0 ml/min. Separation variable (Table 2) was set and 
mobile phase was allowed to saturate the column at 1.0 
ml/min. After complete saturation of column, six replicates 
of reference standard, 15μg/ml of ASP, CLOP and 2μg/ml of 
ROS were injected separately. Peak report and column 
performance report were recorded. The chromatogram was 
recorded at 242 nm Figure 2. The peak areas were plotted 
against the corresponding concentrations to obtain the 
calibration graph Figure 3-5. The result of their optical 
characteristics and linearity data of all three drugs has been 
reported in the Table 3. 
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Figure 2: HPLC chromatogram of CLOP 15μg/ml, ROS 2μg/ml and ASP 15μg/ml standard 
 
 
Figure 3: Calibration curve of ASP 
 
Figure 4: Calibration curve of CLOP 
 
Figure 5: Calibration curve of ROS 
 
Method Validation 
Linearity 
The proposed method was found to be linear in the range of 
7.5-22.5μg/ml and 1-3μg/ml for ASP, CLOP and ROS 
respectively with correlation coefficient 0.9998, 0.9997 and 
0.9997 for ASP, CLOP and ROS respectively. Linearity of ASP, 
CLOP and ROS were established by response ratios of drug. 
Response ratio of three drugs was calculated by dividing the 
absorbance or peak area with respective concentration 
(Table 4). 
Specificity 
Specificity of the method was carried out to assess 
unequivocally the analyte presence of the components that 
might be expected to be present, such as matrix components. 
The result of specificity is shown in Figure 6 and Figure 7 as 
compare to blank, there was no interference seen in 
chromatogram. 
Precision 
Precision of the methods was studied at three levels as at 
repeatability, intermediate precision (Day to Day and analyst 
to analyst) and reproducibility (Table 5). 
Accuracy 
The validity and reliability of proposed methods were 
assessed by recovery studies. The recovery of added 
standards (80 %, 100 % and 120 %) was found at five 
replicate and five concentrations level. The values of % mean 
just close to 100, SD and % RSD were less than 2 which 
indicate the accuracy of method. Result of recovery study is 
shown in Table 6. 
Robustness 
The robustness of developed method was checked by 
changing in the deliberate variation in solvent. Result of 
robustness is shown in Table 7-9. 
LOD and LOQ 
Detection limit and Quantitation limit of described method 
were observed as 0.300 mg/ml and 0.909 µg/ml for ASP, 
0.372 µg/ml and 1.127 µg/ml for CLOP, 0.050 µg/ml and 
0.153 µg/ml for ROS, based on the SD of response and slope, 
which meet the requirement of new method. 
Assay of marketed formulation 
The results of the analysis of capsule formulation (Rosumac-
Gold) were reported. The assay value of ASP, CLOP and ROS 
were close to 100, SD and % RSD are less than 2 which 
indicate that the no interference of excipient in the 
estimation of ASP, CLOP and ROS was observed. The 
statistical evaluation of tablet analysis by methods has been 
reported in Table 10. 
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Figure 6: Chromatogram of blank 
 
Figure 7: Chromatogram of ASP, CLOP and ROS at 242 nm 
Table 1: Results of system suitability parameters 
Parameters ASP CLOP ROS 
Retention time 3.103  ± 0.5 4,277± 0.5 5.707 ± 0.5 
Number of theoretical plates 7103 3127 7047 
Asymmetry 1.333 1.349 1.389 
Resolution - 5.178 4.950 
HETP 0.036±0.003 0.080±0.005 0.036±0.004 
Tailing factor 1.10 ± 0.017 1.60 ± 0.02 1.85 ± 0.03 
 
Table 2: Separation variable of RP-HPLC method 
Variable Condition 
Column  
Dimension 250 mm x 4.60 mm 
Particle size 5 µ 
Bonded phase Octadecylsilane (C18) 
Mobile phase  
Acetonitrile 40% 
Phosphate buffer ( pH- 6.0) 60% 
Diluent ACN: phosphate buffer pH-6.0 (40:60 v/v) 
Flow rate 1.0 ml/min 
Temperature 250C 
Sample size 20 µl 
Detection wavelength 242 nm 
Retention time  
ASP 3.103 ± 0.5 min 
CLOP 4.277± 0.5 min 
ROS 5.707 ± 0.5min 
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Table 3: Optical characteristics and linearity data of ASP, CLOP and ROS 
S. No. Parameters RP-HPLC Method 
  ASP CLOP ROS 
1 Working λ 242 242 242 
2 Concentration (μg/ml) 7.5-22.5 7.5-22.5 1-3 
3 Correlation Coefficient (r2)* 0.9998 0.9997 0.9997 
4 Slope (m)* 50.648 94.268 95.807 
5 Intercept (c)* 15.362 39.298 4.167 
*Average of five determinations 
Table 4: Response ratios of ASP, CLOP and ROS 
 Concentration (µg/ml) RP-HPLC Method 
             ASP                       CLOP                   ROS 
 ASP CLOP ROS AUC RR AUC RR AUC RR 
1 7.5 7.5 1 391.770 52.24 737.476 98.33 99.041 99.05 
2 11.25 11.25 1.5 589.880 52.44 1110.143 98.68 149.238 99.49 
3 15 15 2 777.287 51.82 1460.509 97.37 196.454 98.23 
4 18.75 18.75 2.5 960.235 51.22 1796.795 95.83 241.987 96.80 
5 22.5 22.5 3 1156.244 51.39 2161.677 96.08 292.183 97.40 
 
Table 5: Results of precision 
Parameter MEAN ± SD* % RSD* 
ASP CLOP  ROS ASP CLOP  ROS 
Repeatability 766.039 ±6.151 1440.355±9.749 193.717 ±1.407 0.803 0.677 0.726 
Intermediate precision 
Day to day  772.891±1.812 1450.116±6.167 195.342±0.457 0.234 0.425 0.234 
Analyst to Analyst 770.302±6.662 1444.768±12.82 194.136±2.583 0.865 0.887 1.331 
Reproducibility 768.302±3.362 1445.106±4.167 195.142±0.257 0.334 0.625 0.534 
*Value of five replicate and five concentrations 
Table 6: Results of recovery study 
% Level % Mean ± SD* % RSD* 
ASP CLOP ROS ASP CLOP ROS ASP CLOP ROS 
80% 80% 80% 101.44 ± 1.31 100.52±1.02 101.44 ±1.30 1.29 1.01 1.28 
100% 100% 100% 100.61 ± 0.35 99.68 ± 0.48 99.53 ± 1.26 0.34 1.26 1.26 
120% 120% 120% 100.47 ± 0.43 99.49 ± 1.01 100.15 ± 0.43 0.42 0.42 0.42 
*Value of five replicate and five concentrations 
Table 7: Robustness data for ASP 
S. NO. 
Area at 
Flow rate 
(- 0.2 ml/min) 
Area at 
Flow rate 
(+ 0.2 ml/min) 
Area at 
pH (- 0.2) 
Area at 
pH (+ 0.2) 
Area at 
Mobile phase(-2) 
Area at 
Mobile 
phase(+2) 
1 791.799 750.453 755.756 782.697 788.641 757.377 
2 789.433 748.149 744.792 772.638 784.491 746.286 
3 793.253 742.879 746.564 788.252 789.617 748.982 
% R.S.D 0.244 0.520 0.786 1.013 0.346 0.770 
 
Table 8: Robustness data for CLOP 
S. NO. 
Area at Flow rate 
(- 0.2 ml/min) 
Area at Flow rate 
(+ 0.2 ml/min) 
Area at 
pH (-0.2) 
Area at 
pH (+0.2) 
Area at Mobile 
phase(-2) 
Area at Mobile 
phase(+2) 
1 1489.304 1409.786 1420.121 1470.654 1482.282 1422.862 
2 1481.987 1405.584 1406.366 1469.489 1485.583 1414.605 
3 1490.791 1388.418 1403.054 1481.036 1485.181 1407.215 
% R.S.D 0.317 0.808 0.642 0.431 0.121 0.553 
 
Table 9: Robustness data for ROS 
SR NO. 
Area at Flow rate 
(- 0.2 ml/min) 
Area at Flow rate 
(+ 0.2 ml/min) 
Area at 
pH (- 0.2) 
Area at 
pH (+ 0.2) 
Area at Mobile 
phase(-2) 
Area at Mobile 
phase(+2) 
1 200.307 189.632 190.997 197.808 199.378 191.379 
2 198.056 189.070 190.247 198.015 200.368 190.809 
3 200.508 186.485 188.723 199.201 199.758 189.267 
% R.S.D 0.682 0.891 0.610 0.379 0.250 0.574 
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Table 10: Analysis on marketed formulation 
Capsule Rosumac Gold 
Label claim CLO (75mg) ROS (10mg) ASP (75mg) 
Assay (% of label claim*)  
Mean ± S. D. 
99.060±0.384 99.485±0.311 100.036±0.679 
 
CONCLUSION 
In summary, we have developed and validated a rapid, 
specific, reproducible RP-HPLC method to quantify ASP, 
CLOP and ROS simultaneously. So far no published methods 
are available for the simultaneous quantification of these 
three drugs in capsule dosage form. To the best of our 
knowledge, this is the first time that all three analytes were 
estimated simultaneously in any of the capsule dosage form. 
The cost-effectiveness, simplicity of the assay is that sample 
turnover rate of less than 7 minutes per sample; make it an 
attractive procedure in high-throughput analysis of ASP, 
CLOP and ROS. From the results of all the validation 
parameters, we can conclude that the developed method can 
be useful for routine analysis and therapeutic drug 
monitoring with desired precision and accuracy. 
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